Immunovant, Inc.IMVT決算レポート
Nasdaq · ヘルスケア · 生物製品（診断物質を含まない）
Immunovant社は臨床段階のバイオ医薬品企業で、重篤かつ稀な自己免疫疾患や炎症性疾患の患者向けの新規モノクローナル抗体療法の開発に注力しています。主力開発候補は複数の自己免疫適応症を対象とし、世界的な市場展開戦略を進めています。
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 55.30% | 79.8M | — | 2023-10-04 |
| FMR LLC | 8.56% | 12.5M | ▲ +3.12pp | 2024-11-12 |
| Deep Track Capital, LP | 0.69% | 1.0M | — | 2024-02-14 |
インサイダー取引
Net 90d: −$9.51M · buys $0 / sells $9.51M期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-04-08 | Van Tuyl Christopher | Chief Legal Officer | Sell (open market) | 5.2K | $24.83 | $128.2K |
| 2026-04-08 | Stout Jay S | Chief Technology Officer | Sell (open market) | 8.6K | $24.83 | $213.9K |
| 2026-04-08 | Stout Jay S | Chief Technology Officer | Sell (open market) | 1.5K | $24.83 | $37.7K |
| 2026-04-08 | Melanie Gloria | Chief Operating Officer | Sell (open market) | 8.7K | $24.83 | $216.6K |
| 2026-04-07 | Hughes Douglas J. | Director | Grant | 13.9K | $0.00 | $0 |
| 2026-04-07 | Frank Torti | Director | Grant | 174.2K | $0.00 | $0 |
| 2026-04-07 | Jake Bauer | Director | Grant | 13.9K | $0.00 | $0 |
| 2026-04-07 | Atul Pande | Director | Grant | 13.9K | $0.00 | $0 |
| 2026-04-07 | Melanie Gloria | Chief Operating Officer | Grant | 83.7K | $0.00 | $0 |
| 2026-04-07 | Susman Robert Graham | Director | Grant | 13.9K | $0.00 | $0 |
1–10 of 23
1 / 3 ページ